Sort
53,477 grants matching “addiction”
Buprenorphine treatment at syringe exchanges to reduce opioid misuse and HIV risk
$723,410Aaron D Fox · Albert Einstein College Of Medicine · R01 · FY2021 · DA
Smokescreen Translational (TL) Analysis Platform
$723,403James William Baurley · Biorealm · R44 · FY2018 · AA
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse
$723,314Joan Weinberger Berman · Albert Einstein College Of Medicine · R01 · FY2019 · DA
Integrating Addiction Research in Health Systems: The Addiction Research Network
$723,265Cynthia I Campbell · Kaiser Foundation Research Institute · UG1 · FY2018 · DA
Project 3: Perception of Tobacco Use in Vulnerable Populations
$723,171Herman Alfred Taylor · American Heart Association · P50 · FY2013 · HL
Does Abstinence from E-cigarettes Produce Withdrawal Symptoms?
$723,010John R Hughes · University Of Vermont & St Agric College · R01 · FY2016 · CA
Understanding neuronal subtype-specific function of NAc in cocaine addiction
$723,004Yi Zhang · Boston Children'S Hospital · R01 · FY2022 · DA
Understanding neuronal subtype-specific function of NAc in cocaine addiction
$723,004Yi Zhang · Boston Children'S Hospital · R01 · FY2023 · DA
Understanding neuronal subtype-specific function of NAc in cocaine addiction
$723,004Yi Zhang · Boston Children'S Hospital · R01 · FY2025 · DA
Understanding neuronal subtype-specific function of NAc in cocaine addiction
$723,004Yi Zhang · Boston Children'S Hospital · R01 · FY2024 · DA
HIV Infection, Cocaine Use and Coronary Artery Disease in HIV+ African Americans
$722,940Shenghan Lai · Johns Hopkins University · R01 · FY2012 · DA
Safety, pharmacokinetics and efficacy of extended-release naltrexone in pregnant women with opioid use disorder
$722,799Elisha Wachman · Boston Medical Center · R01 · FY2018 · HD
Early Stress and the Neurobiology of Susceptibility and Resilience to Substance Use Disorders
$722,756Martin H Teicher · Mclean Hospital · R01 · FY2020 · DA
Biased Kappa Opioid Agonists as Non-addictive Analgesics
$722,715Thomas J Martin · Wake Forest University Health Sciences · R01 · FY2023 · DA
Inter-Temporal Trade-offs in the Risky Decisions of Cocaine Addicts
$722,659Warren K Bickel · Virginia Polytechnic Inst And St Univ · R01 · FY2011 · DA
Effects of Early Life Adversity on Substance Use Problems in Adolescents: Biobehavioral Risk Mechanisms
$722,597Uma Rao · University Of California-Irvine · R01 · FY2023 · DA
The circadian rhythm as a lentiviral vector restriction factor
$722,551Tal Kafri · Univ Of North Carolina Chapel Hill · R01 · FY2023 · HL
Pathways to Recovery: Older Substance Users
$722,478Christy K Scott · Chestnut Health Systems, Inc. · R01 · FY2013 · DA
HERV proteogenomics of narcotic-driven HIV latency
$722,475Lubbertus C Mulder · Icahn School Of Medicine At Mount Sinai · R61 · FY2024 · DA
HERV proteogenomics of narcotic-driven HIV latency
$722,475Lubbertus C Mulder · Icahn School Of Medicine At Mount Sinai · R61 · FY2025 · DA
HERV proteogenomics of narcotic-driven HIV latency
$722,475Lubbertus C Mulder · Icahn School Of Medicine At Mount Sinai · R61 · FY2023 · DA
Pharmacogenetics of Nicotine Addiction Treatment
$722,396Caryn Lerman · University Of Pennsylvania · U01 · FY2012 · DA
A patient self-assessment software combining compliance protocols to improve prescriber confidence, reduce liability, and improve patient outcomes.
$722,339Abraham G Hartzema · Clarity, Llc · R44 · FY2020 · DA
Implementing contingency management in opioid treatment centers across New England: A hybrid type 3 trial
$722,325Sara Becker · Northwestern University At Chicago · R01 · FY2022 · DA
Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications, and CBT4CBT: A randomized clinical trial in a diverse patient population
$722,268E. Jennifer Edelman · Yale University · R01 · FY2024 · AA